Two Sigma Advisers LP Has $1.14 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Two Sigma Advisers LP boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 195.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 41,100 shares of the company's stock after acquiring an additional 27,200 shares during the quarter. Two Sigma Advisers LP owned approximately 0.06% of Akero Therapeutics worth $1,143,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its position in shares of Akero Therapeutics by 127.9% during the third quarter. Barclays PLC now owns 127,668 shares of the company's stock worth $3,662,000 after purchasing an additional 71,652 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Akero Therapeutics by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company's stock worth $412,000 after purchasing an additional 1,446 shares during the last quarter. abrdn plc lifted its holdings in Akero Therapeutics by 118.7% during the 4th quarter. abrdn plc now owns 269,782 shares of the company's stock worth $7,505,000 after buying an additional 146,424 shares in the last quarter. Rhumbline Advisers lifted its holdings in Akero Therapeutics by 1.3% during the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company's stock worth $2,940,000 after buying an additional 1,310 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its position in Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock valued at $584,000 after buying an additional 1,000 shares during the last quarter.

Akero Therapeutics Trading Up 2.0%

AKRO stock traded up $1.05 during midday trading on Wednesday, hitting $52.66. 358,590 shares of the company's stock were exchanged, compared to its average volume of 988,385. Akero Therapeutics, Inc. has a one year low of $17.86 and a one year high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The company has a market cap of $4.20 billion, a PE ratio of -14.05 and a beta of -0.12. The stock's fifty day moving average price is $41.52 and its 200-day moving average price is $39.09.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. Research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright upped their price target on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Bank of America raised their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Finally, Citigroup lowered their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $82.50.

Insider Buying and Selling

In other Akero Therapeutics news, insider Catriona Yale sold 10,000 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $39.30, for a total transaction of $393,000.00. Following the completion of the transaction, the insider now owns 95,034 shares in the company, valued at approximately $3,734,836.20. This represents a 9.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Patrick Lamy sold 4,000 shares of Akero Therapeutics stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $50.00, for a total value of $200,000.00. Following the completion of the sale, the vice president now directly owns 33,492 shares in the company, valued at $1,674,600. This represents a 10.67% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 159,708 shares of company stock valued at $6,465,579. 7.94% of the stock is owned by corporate insiders.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.